Domača stranGBT • EPA
add
Guerbet SA
Prejšnji trg. dan.
14,74 €
Dnevni razpon
14,66 € - 14,78 €
Letni razpon
12,72 € - 39,35 €
Tržna kapitalizacija
185,82 mio. EUR
Povprečni obseg
42,85 tis.
Razm. P/E
36,17
Dividendna donosnost
-
Primarna borza
EPA
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | jun. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 197,36 mio. | −7,11 % |
Stroški poslovanja | 149,62 mio. | −3,00 % |
Čisti dohodek | 1,32 mio. | −76,01 % |
Čista dobičkovnost prihodkov | 0,67 | −74,03 % |
Earnings per share | — | — |
EBITDA | 22,20 mio. | −26,51 % |
Efektivna davčna stopnja | 50,97 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | jun. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 50,12 mio. | 28,36 % |
Skupna sredstva | 1,02 mrd. | −2,39 % |
Skupne obveznosti | 644,94 mio. | −1,44 % |
Celoten lastniški kapital | 372,13 mio. | — |
Shares outstanding | 12,60 mio. | — |
Razmerje P/B | 0,49 | — |
Donosnost sredstev | 1,84 % | — |
Donosnost kapitala | 2,42 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | jun. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,32 mio. | −76,01 % |
Denar iz dejavnosti | 11,27 mio. | 121,77 % |
Denar iz naložb | −7,74 mio. | 34,85 % |
Denar iz financiranja | −2,44 mio. | −335,94 % |
Neto sprememba denarnih sredstev | −123,50 tis. | 97,98 % |
Prost denarni tok | 14,24 mio. | 44,21 % |
Vizitka
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product will be produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories.
An analysis of the growing global contrast media market, valued at $6.19 billion 2023 US dollars described Guerbet as a "key player." Wikipedia
Generalni direktor
Datum ustanovitve
1926
Spletno mesto
Zaposleni
2.842
